Supplementary file 1b.

Evaluation of cell-free urine microRNAs expression for the use in diagnosis of ovarian and endometrial cancers. A pilot study

Pathology & Oncology Research

Authors: LuděkZáveský, Eva Jandáková, Radovan Turyna, LucieLangmeierová, Vít Weinberger, LenkaZáveskáDrábková, Martina Hůlková, AlešHořínek, Daniela Dušková, Jaroslav Feyereisl, LubošMinář, MiladaKohoutová

Corresponding author: RNDr. LuděkZáveský, Ph.D., Institute of Biology and Medical Genetics, the First Faculty of Medicine, Charles University Prague and General University Hospital in Prague, Albertov 4, CZ-128 00 Prague 2, the Czech Republic; e-mail:

Table SF1b. Fold-differencesofpathologicalsamplescompared to controls (S2E experiment)

Sample / MicroRNA and folddifferences to controlsamples
Pre-surgerypathologicalsamples A / miR-21 / miR-223 / miR-200b / miR-16 / miR-29a / miR-367 / miR-106b / miR-100 / miR-20a / miR-1228
Ovariancancer
UCB315A / 0.42 / 1.5 / n/a / n/a / 0.25 / 4.75 / 0.38 / 0.7 / n/a / 0.35
UCP12 / 1.2 / n/a / 1.8 / 1.9 / 1.44 / 0.37 / 0.11 / 1.44 / 0.59 / 2.21
UCP5A (mixed) / 0.21 / n/a / 0.64 / 0.62 / 1.42 / 2.57 / 0.35 / 0.44 / 0.69 / 4.45
UCB318C (post-surgery, post-chemotherapy) / 2.79 / 0.1 / 1.61 / 1.2 / 1.99 / 1.94 / 0.3 / 1.83 / 1.6 / 0.16
Endometrialcancer
UCP8 / 4.41 / 1.72 / 0.34 / 2.3 / 0.62 / n/a / 0.23 / 2.25 / 2.2 / 0.08
UCP9 / 0.19 / n/a / n/a / 0.21 / n/a / 3.54 / n/a / n/a / n/a / 1.33
UCP11 / 2.66 / 0.32 / 1.64 / 1.38 / 0.75 / n/a / 0.18 / 1.85 / 1.53 / 0.42
UCP13 / 2.7 / n/a / n/a / 0.32 / n/a / n/a / n/a / n/a / n/a / 0.45
UCP15 / 4.15 / 0.32 / n/a / 2.88 / 0.44 / n/a / 0.43 / 1.32 / 1.62 / n/a
Benignsamples (ovarian)
UFB01 / 3.47 / n/a / 1.17 / 1.18 / 0.8 / n/a / n/a / 3.15 / 1.47 / n/a
UCP14 / 1.67 / n/a / n/a / 1.38 / 0.49 / n/a / 0.2 / 1.19 / 0.88 / 0.82
Benignsamples (endometrial)
UCP7 / 0.39 / n/a / 1.51 / 1.18 / 0.31 / 4.3 / 0.28 / 1.4 / 1.41 / 0.28
UCP10 / 7.71 / 0.13 / 0.57 / 1.76 / 1.3 / 0.98 / 0.17 / 2.16 / 1.89 / 0.27

1